CVR number 41912367
Industry 21.1000 Manufacture of basic pharmaceutical products

Nature's BioCeuticals Denmark ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 8.1% 19.2% 17.1% 12.1%  
Credit score (0-100)  0 30 6 9 18  
Credit rating  N/A BB B BB BB  
Credit limit (kDKK)  0.0 0.0 -0.0 -0.0 -0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  0.0 -14.6 -944 -849 -400  
EBITDA  0.0 -14.6 -944 -849 -400  
EBIT  0.0 -24.6 -1,421 -1,326 -878  
Pre-tax profit (PTP)  0.0 -24.6 -1,521.8 -1,431.7 -897.6  
Net earnings  0.0 -20.0 -1,517.1 -1,434.9 -897.6  
Pre-tax profit without non-rec. items  0.0 -24.6 -1,517 -1,432 -898  
 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 14,245 13,778 13,310  
Shareholders equity total  0.0 20.0 -1,497 -1,152 -2,050  
Interest-bearing liabilities  0.0 0.0 200 0.0 0.0  
Balance sheet total (assets)  0.0 230 14,482 14,051 13,671  
Net Debt  0.0 -35.4 200 -0.1 -0.1  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -14.6 -944 -849 -400  
Gross profit growth  0.0% 0.0% -6,353.2% 10.1% 52.8%  
Employees  0 0 1 0 0  
Employee growth %  0.0% 0.0% 0.0% -100.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 230 14,482 14,051 13,671  
Balance sheet change%  0.0% 0.0% 6,197.0% -3.0% -2.7%  
Added value  0.0 -14.6 -943.9 -848.6 -400.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 180 13,758 -954 -954  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 168.4% 150.6% 156.2% 219.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -10.7% -17.5% -8.5% -5.7%  
ROI %  0.0% -11.2% -676.8% -1,325.9% 0.0%  
ROE %  0.0% -100.2% -20.9% -10.1% -6.5%  

Solidity 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  0.0% 8.7% -9.4% -7.6% -13.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 241.8% -21.2% 0.0% 0.0%  
Gearing %  0.0% 0.0% -13.4% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 96.0% 105.8% 0.0%  

Liquidity 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.0 4.0 1.2 0.7 1.9  
Current Ratio  0.0 4.0 1.2 0.7 1.9  
Cash and cash equivalent  0.0 35.4 0.1 0.1 0.1  

Capital use efficiency 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 30.0 8.1 -53.5 44.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 -944 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 -944 0 0  
EBIT / employee  0 0 -1,421 0 0  
Net earnings / employee  0 0 -1,517 0 0